{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:09:23Z","timestamp":1790208563964,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Multiparametric MRI is the current standard for detecting clinically significant prostate cancer (csPCa). However, men with negative or equivocal MRI often undergo unnecessary biopsies due to concerns about false-negative results. The recently proposed <jats:sup>68<\/jats:sup>Ga-PSMA PET\/CT-based PRIMARY score exhibited good diagnostic performance for csPCa. This study aimed to externally validate the performance of the PRIMARY score and evaluate its added diagnostic value to MRI triage in detecting csPCa.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>This retrospective cohort study included 431 men who underwent both <jats:sup>68<\/jats:sup>Ga-PSMA PET\/CT and MRI before biopsy. Performance was assessed using the area under the receiver operating characteristic curve and the decision curve analysis. The PRIMARY score + MRI was considered positive for either PRIMARY score 3\u20135 or Prostate Imaging Reporting and Data System (PI-RADS) 4\/5.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The prevalence of csPCa was 51.7% (223\/431). The area under the receiver operating characteristic curve of the 5-level PRIMARY score for csPCa was significantly higher than that of MRI (0.873 vs 0.786, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). For the entire group, sensitivity, specificity, positive predictive value, and negative predictive value of the PRIMARY score were 90.6%, 61.1%, 71.4%, and 85.8%, respectively, which outperformed 87.9%, 49.0%, 64.9%, and 79.1% of PI-RADS on MRI. The PRIAMRY score + MRI improved sensitivity (96.0% vs 87.9%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and negative predictive value (91.5% vs 79.1%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) without compromising specificity and positive predictive value compared with MRI alone. This combined approach avoided 24.6% (106\/431) of unnecessary biopsies, while missing 4.0% (9\/223) of csPCa cases. The addition of the PRIMARY score in men with PI-RADS 1\u20133 showed a net benefit, but not in men with PI-RADS 4\/5.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The PRIMARY score was superior to MRI in detecting csPCa, and its added diagnostic value was in men with negative or equivocal MRI results. The PRIMARY score + MRI improved negative predictive value and sensitivity for csPCa compared with MRI alone. Further prospective trials will validate whether men with clinical suspicion of csPCa but negative PRIMARY score + MRI can safely avoid unnecessary biopsies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004951","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:15Z","timestamp":1702339215000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["The PRIMARY Score"],"prefix":"10.1097","volume":"49","author":[{"given":"Shikuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Kang","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaijun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi\u2019an, Shaanxi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi\u2019an, Shaanxi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ren","sequence":"additional","affiliation":[{"name":"Radiology, Xijing Hospital, Fourth Military Medical University, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi\u2019an, Shaanxi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi\u2019an, Shaanxi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","year":"2021","journal-title":"Eur Urol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JU.0000000000000617","article-title":"Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer","volume":"203","year":"2020","journal-title":"J Urol"},{"key":"bib3-20250621","first-page":"CD012663","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2019.05.004","article-title":"Comparison of magnetic resonance imaging\u2013stratified clinical pathways and systematic transrectal ultrasound-guided biopsy pathway for the detection of clinically significant prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"2","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","article-title":"Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis","volume":"78","year":"2020","journal-title":"Eur Urol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"bib7-20250621","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","year":"2023","journal-title":"Eur Urol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.nucmedbio.2013.09.002","article-title":"Cationic eluate pretreatment for automated synthesis of [68Ga]CPCR4.2","volume":"41","year":"2014","journal-title":"Nucl Med Biol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging\u2013reporting and data system: 2015, version 2","volume":"69","year":"2016","journal-title":"Eur Urol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","year":"2019","journal-title":"Eur Urol"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"122","DOI":"10.7326\/M13-1522","article-title":"Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician\u2019s guide","volume":"160","year":"2014","journal-title":"Ann Intern Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1191\/1740774506cn147oa","article-title":"Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs","volume":"3","year":"2006","journal-title":"Clin Trials"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","year":"2006","journal-title":"Med Decis Making"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/00000478-198812000-00001","article-title":"Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread","volume":"12","year":"1988","journal-title":"Am J Surg Pathol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"8396","DOI":"10.7150\/thno.58140","article-title":"Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET\/CT: a real-world study","volume":"11","year":"2021","journal-title":"Theranostics"},{"key":"bib19-20250621","first-page":"67","article-title":"PSMA uptake on [68Ga]-PSMA-11-PET\/CT positively correlates with prostate cancer aggressiveness","volume":"66","year":"2022","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MNM.0000000000000942","article-title":"Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer?","volume":"40","year":"2019","journal-title":"Nucl Med Commun"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","article-title":"68Ga-PSMA PET\/CT detects the location and extent of primary prostate cancer","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.115.169243","article-title":"Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/JU.0000000000001200","article-title":"Interreader agreement with prostate imaging reporting and data system version 2 for prostate cancer detection: a systematic review and meta-analysis","volume":"204","year":"2020","journal-title":"J Urol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000474716","article-title":"Influence of prostatic disease and prostatic manipulations on the concentration of prostate-specific antigen","volume":"22","year":"1992","journal-title":"Eur Urol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","year":"2017","journal-title":"JAMA"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1741-7015-12-26","article-title":"Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen","volume":"12","year":"2014","journal-title":"BMC Med"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.juro.2017.10.021","article-title":"Use of digital rectal examination as an adjunct to prostate specific antigen in the detection of clinically significant prostate cancer","volume":"199","year":"2018","journal-title":"J Urol"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bju.15876","article-title":"Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial","volume":"131","year":"2023","journal-title":"BJU Int"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1007\/s00330-020-06958-8","article-title":"Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation","volume":"30","year":"2020","journal-title":"Eur Radiol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1148\/radiol.16151133","article-title":"Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers","volume":"280","year":"2016","journal-title":"Radiology"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","year":"2021","journal-title":"Eur Urol"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter","volume":"350","year":"2004","journal-title":"N Engl J Med"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/jnci\/djt151","article-title":"Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men","volume":"105","year":"2013","journal-title":"J Natl Cancer Inst"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:04:26Z","timestamp":1750532666000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004951"}},"subtitle":["Diagnostic Performance and Added Value Compared With MRI in Detecting Clinically Significant Prostate Cancer"],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004951","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,29]]}}}